首页> 外文期刊>The Journal of Antimicrobial Chemotherapy >Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections
【24h】

Impact on hospital mortality of catheter removal and adequate antifungal therapy in Candida spp. bloodstream infections

机译:念珠菌中导管拔除和适当的抗真菌治疗对医院死亡率的影响。血液感染

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objectives: We set out to identify the prognostic factors in adult patients with Candida spp. bloodstream infection, assessing the impact on in-hospital mortality of catheter removal and adequacy of antifungal therapy. Methods: Patients with positive blood culture for Candida spp. and a central venous catheter in place at the time of candidaemia were included. Data collected included demographics, underlying diseases, severity of illness, clinical presentation, catheter withdrawal and adequacy of empirical therapy. Results: We included 188 patients (mortality 36.7%). The mortality rate was 34.9% (23/66) in patients with early adequate antifungal treatment and 18.9% (7/37) in patients with early adequate antifungal therapy and catheter withdrawal in the first 48 h. The APACHE (Acute Physiology and Chronic Health Evaluation) II score on the day of candidaemia [adjusted hazard ratio (aHR) 1.12; 95% CI 1.06-1.17; P < 0.001] was associated with death whereas early adequate therapy (aHR 0.4; 95% CI 0.23-0.83; P = 0.012) and catheter withdrawal (aHR 0.34; 95% CI 0.16-0.70; P = 0.03) were protective factors. In primary candidaemia, mortality was 28% (14/50) in patients with adequate therapy and decreased to 17.7% (6/34) in patients with both interventions in the first 48 h. Catheter removal was a protective factor and adequacy of antifungal therapy in the first 48 h showed a strong tendency to protection against death (aHR 0.46; 95% CI 0.19-1.08; P = 0.07). In secondary non-catheter-related candidaemia, only early adequate therapy was a protective factor for mortality. Conclusions: Delay in catheter withdrawal and in administration of adequate antifungal therapy was associated with increased mortality in candidaemic patients. Catheter management did not influence the prognosis of secondary non-catheter-related candidaemia.
机译:目的:我们着手确定成人念珠菌属患者的预后因素。血液感染,评估导管拔除对抗真菌治疗的院内死亡率的影响。方法:血液培养阳性的念珠菌属患者。并包括念珠菌血症时就位的中央静脉导管。收集的数据包括人口统计学,潜在疾病,疾病严重程度,临床表现,导管撤回和经验疗法的充分性。结果:我们纳入了188例患者(死亡率36.7%)。进行早期适当的抗真菌治疗的患者在开始的48小时内,死亡率为34.9%(23/66),而进行早期适当的抗真菌治疗和撤回导管的患者的死亡率为18.9%(7/37)。念珠菌病发生当天的APACHE(急性生理和慢性健康评估)II评分[调整后的危险比(aHR)1.12; 95%CI 1.06-1.17; P <0.001]与死亡相关,而早期适当治疗(aHR 0.4; 95%CI 0.23-0.83; P = 0.012)和导管撤回(aHR 0.34; 95%CI 0.16-0.70; P = 0.03)是保护因素。在原发性念珠菌血症中,经过适当治疗的患者的死亡率为28%(14/50),而在最初的48小时中,两种干预措施的患者死亡率均降低至17.7%(6/34)。拔除导管是一个保护因素,在开始的48小时内抗真菌治疗的充分性显示出很强的防止死亡的趋势(aHR 0.46; 95%CI 0.19-1.08; P = 0.07)。在继发性非导管相关性念珠菌血症中,只有早期适当的治疗才是死亡率的保护因素。结论:念珠菌病患者延迟撤回导管和进行适当的抗真菌治疗与死亡率增加有关。导管管理不影响继发性非导管相关念珠菌血症的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号